The case for & against
Bull & Bear analysis
Amgen Inc. (NASDAQ: AMGN) is a prominent player in the biotechnology sector specializing in the development of biopharmaceuticals to address significant medical challenges. Positioned in multiple therapeutic areas, including oncology, cardiovascular health, inflammation, and rare diseases, Amgen leverages its extensive product portfolio to drive growth while navigating an evolving healthcare landscape. The company is currently focusing on its innovative pipeline, particularly with emerging treatments like Meritide, which positions it well within the booming obesity treatment market.
Bull says
- ↑Revenue rose 9% YoY to $8.1B, driven by 14% volume growth
- ↑Non-GAAP operating margin of 45% highlights strong profitability
- ↑Q1 free cash flow of $1.9B supports R&D and dividends
- ↑Meritide obesity pipeline and FDA approval of Uplizna expand portfolio
- ↑High earnings yield, robust profitability, and 6% dividend hike appeal to investors
Bear says
- ↓Negative growth trends and severe revision risks signal outlook deterioration
- ↓Accelerated sales erosion from biosimilars targeting Prolia in 2026
- ↓FDA request to withdraw Tavneos heightens regulatory uncertainty
- ↓Capex rising to $2.6B in 2026 pressures cash flow amid sales decline
- ↓Short interest near 0.93 reflects elevated investor skepticism
Investment themes with AMGN
Companies paying above-average dividends
Genetic and drug innovations driving medical breakthroughs
Products and services targeting weight management
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- We had a strong first quarter and are well-positioned to achieve our objectives for the year.
- we're on track to achieve these objectives. With steady execution through the rest of the year, we expect, once again, to demonstrate that we can grow through a period of patent expiration and deliver attractive performance for our shareholders with a strong portfolio of innovative medicines and biosimilars that meet the needs of patients with serious diseases.
- Together, they generated 70% of our sales in the quarter and grew significantly in aggregate, by 24%. That strong performance sets us up well for the year and well beyond.
Bear points
- We expect these factors will continue to negatively impact the cost of sales in future quarters.
- The approach taken by the IRS is similar in nature to our 2010 to 2015 dispute with the IRS currently pending in Tax Court. If sustained in full, the adjustments set forth in the draft NOFA could have a material impact on our financial statements.
- Crowley and Exchiva combined delivered $1.1 billion in sales in the first quarter, a decrease of 32% year-over-year. Erosion since loss of exclusivity remains in line with our expectations, and we anticipate accelerated sales erosion over the remainder of 2026, driven by increased competition from multiple biosimilars.